Gregory Mattingly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2506978/publications.pdf

Version: 2024-02-01

19	302	11	17
papers	citations	h-index	g-index
19	19	19	359
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregivers. CNS Spectrums, 2023, 28, 343-350.	0.7	4
2	Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents. CNS Spectrums, 2022, 27, 199-207.	0.7	10
3	A clinician's guide for navigating the world of attention deficit hyperactivity disorder medications. CNS Spectrums, 2021, 26, 104-114.	0.7	1
4	Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment. Patient Preference and Adherence, 2021, Volume 15, 1061-1073.	0.8	2
5	Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2020, 30. 58-68.	0.7	13
6	Characteristics of ADHD Symptom Response/Remission in a Clinical Trial of Methylphenidate Extended Release. Journal of Clinical Medicine, 2019, 8, 461.	1.0	13
7	Modelling resilience in adolescence and adversity: a novel framework to inform research and practice. Translational Psychiatry, 2019, 9, 316.	2.4	61
8	Relationship Between Symptomatic and Functional Improvement and Remission in a Treatment Response to Stimulant Trial. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 521-529.	0.7	21
9	A clinician's guide to ADHD treatment options. Postgraduate Medicine, 2017, 129, 657-666.	0.9	32
10	Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems. CNS Spectrums, 2016, 21, 45-59.	0.7	11
11	The impact of cognitive challenges in major depression: the role of the primary care physician. Postgraduate Medicine, 2016, 128, 665-671.	0.9	17
12	Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2016, 26, 873-881.	0.7	20
13	Switching to Iloperidone. Clinical Schizophrenia and Related Psychoses, 2015, 8, 183-195.	1.4	6
14	Aiming for remission in adults with attention-deficit/hyperactivity disorder: The primary care goal. Postgraduate Medicine, 2015, 127, 323-329.	0.9	5
15	Response/Remission With Guanfacine Extended-Release and Psychostimulants inÂChildren and Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 1092-1101.	0.3	18
16	A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia. Schizophrenia Research, 2014, 153, 160-168.	1.1	15
17	Attention deficit hyperactivity disorder subtypes and symptom response in adults treated with lisdexamfetamine dimesylate. Innovations in Clinical Neuroscience, 2012, 9, 22-30.	0.1	30
18	Lisdexamfetamine Dimesylate: <i>A Prodrug Stimulant for the Treatment of ADHD in Children and Adults</i> CNS Spectrums, 2010, 15, 315-325.	0.7	23

#	Article	IF	CITATIONS
19	Assessing the educational needs of physicians in the management of patients with Tourette syndrome: results of a United States survey on practicing clinicians and caregivers $\hat{a} \in \text{CORRIGENDUM}$. CNS Spectrums, 0, , 1-1.	0.7	O